<DOC>
	<DOCNO>NCT01426789</DOCNO>
	<brief_summary>This study aim confirm patient specific biomarker might better response secukinumab treatment . To meet purpose , exploratory biomarker study do . The goal exploratory study ( 1 ) find biomarkers identify person rheumatoid arthritis best possible response secukinumab ( 2 ) identify person few side effect order maximize benefit secukinumab .</brief_summary>
	<brief_title>A Biomarker Study Secukinumab Rheumatoid Arthritis ( RA ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis Patients must either DMARD naive fail least one DMARD agent ( e.g . MTX , leflunamide sulfasalazine ) Patients allow 3 DMARDs study entry ( e.g . MTX , sulfasalazine hydroxychloroquine ) long dose stable 4 week prior initiate study treatment Disease activity screening define ≥6 28 tender joint ≥6 28 swollen joint hsCRP &gt; 10mg/L Patients severe rheumatoid arthritis ( functional status class IV accord ACR 1991 revise criterion ) Previous exposure secukinumab biologic , include TNF inhibitor . Use high potency opioid analgesic Pregnant nursing ( lactate ) woman Use investigational drug RA therapy and/or device time randomization within 30 day 5 halflives randomization , whichever longer . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>IgG1K monoclonal antibody</keyword>
	<keyword>Interleukin-17A neutralizing</keyword>
</DOC>